Helen Susan Kim
CIK 1422772 · EVP, Business Development · last filed 2026-01-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KITE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
HAYWARD, CA 94545
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKTS | Director | 4,859,370 | $15.73 | $76.44M | $15.03M | 1 | 2026-01-12 |
| PRTA | Director | — | $8.40 | — | $0 | 4 | 2025-05-16 |
| Applied Molecular Transport Inc. (AMTI) Delisted | Director | 575,951 | $0.26 | $151.5K | -$9.42M | 5 | 2021-08-27 |
| ASMB | Director | — | $19.67 | — | $0 | 4 | 2020-06-15 |
| XCUR | Director | — | $1.09 | — | $0 | 1 | 2020-06-08 |
| Kite Pharma, Inc. (KITE) Delisted | EVP, Business Development | 24,864 | — | — | -$19.98M | 12 | 2017-09-27 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | Director | — | $18.62 | — | $0 | 8 | 2015-07-01 |
| ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted | Director | — | — | — | $0 | 2 | 2013-09-24 |
| KOSAN BIOSCIENCES INC (KOSN) Delisted | President and CEO | 10,280 | — | — | $26.6K | 3 | 2008-04-02 |
Recent Filings · Page 2 of 5
45 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-15 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2020-06-08 | XCUR | Grant (A) | — | $0 | EDGAR |
| 2019-06-14 | — | Grant (A) | — | $0 | |
| 2019-05-17 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2018-06-21 | — | Grant (A) | — | $0 | |
| 2018-06-01 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2018-03-12 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2017-10-05 | — | Mixed | −21,693 | -$754.7K | |
| 2017-09-28 | — | Grant (A) | — | $0 | |
| 2017-09-27 | Kite Pharma, Inc. (KITE) Delisted | Mixed | +2,829 | -$569.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.